Cargando…
COVID-19 morbidity in Afghanistan: a nationwide, population-based seroepidemiological study
OBJECTIVE: The primary objectives were to determine the magnitude of COVID-19 infections in the general population and age-specific cumulative incidence, as determined by seropositivity and clinical symptoms of COVID-19, and to determine the magnitude of asymptomatic or subclinical infections. DESIG...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334691/ https://www.ncbi.nlm.nih.gov/pubmed/35896297 http://dx.doi.org/10.1136/bmjopen-2021-060739 |
_version_ | 1784759159446568960 |
---|---|
author | Saeedzai, Sayed Ataullah Sahak, Mohammad Nadir Arifi, Fatima Abdelkreem Aly, Eman van Gurp, Margo White, Lisa J Chen, Siyu Barakat, Amal Azim, Giti Rasoly, Bahara Safi, Soraya Flegg, Jennifer A Ahmed, Nasar Ahadi, Mohmmad Jamaluddin Achakzai, Niaz M AbouZeid, Alaa |
author_facet | Saeedzai, Sayed Ataullah Sahak, Mohammad Nadir Arifi, Fatima Abdelkreem Aly, Eman van Gurp, Margo White, Lisa J Chen, Siyu Barakat, Amal Azim, Giti Rasoly, Bahara Safi, Soraya Flegg, Jennifer A Ahmed, Nasar Ahadi, Mohmmad Jamaluddin Achakzai, Niaz M AbouZeid, Alaa |
author_sort | Saeedzai, Sayed Ataullah |
collection | PubMed |
description | OBJECTIVE: The primary objectives were to determine the magnitude of COVID-19 infections in the general population and age-specific cumulative incidence, as determined by seropositivity and clinical symptoms of COVID-19, and to determine the magnitude of asymptomatic or subclinical infections. DESIGN, SETTING AND PARTICIPANTS: We describe a population-based, cross-sectional, age-stratified seroepidemiological study conducted throughout Afghanistan during June/July 2020. Participants were interviewed to complete a questionnaire, and rapid diagnostic tests were used to test for SARS-CoV-2 antibodies. This national study was conducted in eight regions of Afghanistan plus Kabul province, considered a separate region. The total sample size was 9514, and the number of participants required in each region was estimated proportionally to the population size of each region. For each region, 31–44 enumeration areas (EAs) were randomly selected, and a total of 360 clusters and 16 households per EA were selected using random sampling. To adjust the seroprevalence for test sensitivity and specificity, and seroreversion, Bernoulli’s model methodology was used to infer the population exposure in Afghanistan. OUTCOME MEASURES: The main outcome was to determine the prevalence of current or past COVID-19 infection. RESULTS: The survey revealed that, to July 2020, around 10 million people in Afghanistan (31.5% of the population) had either current or previous COVID-19 infection. By age group, COVID-19 seroprevalence was reported to be 35.1% and 25.3% among participants aged ≥18 and 5–17 years, respectively. This implies that most of the population remained at risk of infection. However, a large proportion of the population had been infected in some localities, for example, Kabul province, where more than half of the population had been infected with COVID-19. CONCLUSION: As most of the population remained at risk of infection at the time of the study, any lifting of public health and social measures needed to be considered gradually. |
format | Online Article Text |
id | pubmed-9334691 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-93346912022-08-01 COVID-19 morbidity in Afghanistan: a nationwide, population-based seroepidemiological study Saeedzai, Sayed Ataullah Sahak, Mohammad Nadir Arifi, Fatima Abdelkreem Aly, Eman van Gurp, Margo White, Lisa J Chen, Siyu Barakat, Amal Azim, Giti Rasoly, Bahara Safi, Soraya Flegg, Jennifer A Ahmed, Nasar Ahadi, Mohmmad Jamaluddin Achakzai, Niaz M AbouZeid, Alaa BMJ Open Epidemiology OBJECTIVE: The primary objectives were to determine the magnitude of COVID-19 infections in the general population and age-specific cumulative incidence, as determined by seropositivity and clinical symptoms of COVID-19, and to determine the magnitude of asymptomatic or subclinical infections. DESIGN, SETTING AND PARTICIPANTS: We describe a population-based, cross-sectional, age-stratified seroepidemiological study conducted throughout Afghanistan during June/July 2020. Participants were interviewed to complete a questionnaire, and rapid diagnostic tests were used to test for SARS-CoV-2 antibodies. This national study was conducted in eight regions of Afghanistan plus Kabul province, considered a separate region. The total sample size was 9514, and the number of participants required in each region was estimated proportionally to the population size of each region. For each region, 31–44 enumeration areas (EAs) were randomly selected, and a total of 360 clusters and 16 households per EA were selected using random sampling. To adjust the seroprevalence for test sensitivity and specificity, and seroreversion, Bernoulli’s model methodology was used to infer the population exposure in Afghanistan. OUTCOME MEASURES: The main outcome was to determine the prevalence of current or past COVID-19 infection. RESULTS: The survey revealed that, to July 2020, around 10 million people in Afghanistan (31.5% of the population) had either current or previous COVID-19 infection. By age group, COVID-19 seroprevalence was reported to be 35.1% and 25.3% among participants aged ≥18 and 5–17 years, respectively. This implies that most of the population remained at risk of infection. However, a large proportion of the population had been infected in some localities, for example, Kabul province, where more than half of the population had been infected with COVID-19. CONCLUSION: As most of the population remained at risk of infection at the time of the study, any lifting of public health and social measures needed to be considered gradually. BMJ Publishing Group 2022-07-27 /pmc/articles/PMC9334691/ /pubmed/35896297 http://dx.doi.org/10.1136/bmjopen-2021-060739 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Epidemiology Saeedzai, Sayed Ataullah Sahak, Mohammad Nadir Arifi, Fatima Abdelkreem Aly, Eman van Gurp, Margo White, Lisa J Chen, Siyu Barakat, Amal Azim, Giti Rasoly, Bahara Safi, Soraya Flegg, Jennifer A Ahmed, Nasar Ahadi, Mohmmad Jamaluddin Achakzai, Niaz M AbouZeid, Alaa COVID-19 morbidity in Afghanistan: a nationwide, population-based seroepidemiological study |
title | COVID-19 morbidity in Afghanistan: a nationwide, population-based seroepidemiological study |
title_full | COVID-19 morbidity in Afghanistan: a nationwide, population-based seroepidemiological study |
title_fullStr | COVID-19 morbidity in Afghanistan: a nationwide, population-based seroepidemiological study |
title_full_unstemmed | COVID-19 morbidity in Afghanistan: a nationwide, population-based seroepidemiological study |
title_short | COVID-19 morbidity in Afghanistan: a nationwide, population-based seroepidemiological study |
title_sort | covid-19 morbidity in afghanistan: a nationwide, population-based seroepidemiological study |
topic | Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334691/ https://www.ncbi.nlm.nih.gov/pubmed/35896297 http://dx.doi.org/10.1136/bmjopen-2021-060739 |
work_keys_str_mv | AT saeedzaisayedataullah covid19morbidityinafghanistananationwidepopulationbasedseroepidemiologicalstudy AT sahakmohammadnadir covid19morbidityinafghanistananationwidepopulationbasedseroepidemiologicalstudy AT arififatima covid19morbidityinafghanistananationwidepopulationbasedseroepidemiologicalstudy AT abdelkreemalyeman covid19morbidityinafghanistananationwidepopulationbasedseroepidemiologicalstudy AT vangurpmargo covid19morbidityinafghanistananationwidepopulationbasedseroepidemiologicalstudy AT whitelisaj covid19morbidityinafghanistananationwidepopulationbasedseroepidemiologicalstudy AT chensiyu covid19morbidityinafghanistananationwidepopulationbasedseroepidemiologicalstudy AT barakatamal covid19morbidityinafghanistananationwidepopulationbasedseroepidemiologicalstudy AT azimgiti covid19morbidityinafghanistananationwidepopulationbasedseroepidemiologicalstudy AT rasolybahara covid19morbidityinafghanistananationwidepopulationbasedseroepidemiologicalstudy AT safisoraya covid19morbidityinafghanistananationwidepopulationbasedseroepidemiologicalstudy AT fleggjennifera covid19morbidityinafghanistananationwidepopulationbasedseroepidemiologicalstudy AT ahmednasar covid19morbidityinafghanistananationwidepopulationbasedseroepidemiologicalstudy AT ahadimohmmadjamaluddin covid19morbidityinafghanistananationwidepopulationbasedseroepidemiologicalstudy AT achakzainiazm covid19morbidityinafghanistananationwidepopulationbasedseroepidemiologicalstudy AT abouzeidalaa covid19morbidityinafghanistananationwidepopulationbasedseroepidemiologicalstudy |